► Leading more than one hundred scientists of different levels in support of PD animal model, pre-clinical exploratory, GLP Tox and clinical studies, especially in new modalities (cell and gene therapy) • PK • ADA • Translational Sciences/Biomarker ► Building muti-high-dimensional platforms and analytical workflows to support first-in-class drug development: • HD flow cytometry • Single-cell omics • Spatial omics► Leading translational efforts integrating pre-clinical studies in small animal and NHP PD/Tox models and Phase I/II clinical studies► Developing/implementing translational/bioanalytical strategies for new modalities: • Antibodies: bi/tri/quad -specifics • ADCs • Cell therapy • Gene therapy • Oncolytic virus • Oligonucleotides► Conducting research projects supported by national funding► Mentoring post-graduates

Lead in pre-clinical and clinical bioanalysis / biomarker

Biomarker Assay Lead► Immuno-oncology: o PK, PD and immuno-assay for cell therapy and bi-specific projects o Biomarker identification and evaluation► GLP toxicity study: PD► High dimensional flow cytometry (spectral flow, 29 colors); high-dimensional data analysis

Study and Team Leader► Authored SOPs/reports for Immunogenicity (ADA) method development, validation and sample analysis (LIMS) for GLP studies (First in house)► Led a team of scientists developing and validating an innovative immunogenicity assessment assay with regulatory compliance

Project/Team Leader Authored eleven papers  Extensive research interests and experience in immunology  Projects includes: o Immuno-tolerance/rejection o Memory B cells o Tfh development o Immuno-oncology o Vaccine/adjuvant: Self-assembling, non-inflammatory  Hardcore user of multi-color flow cytometry and ELISOPT